Pleural Diseases Market Report 2025

The pleural diseases market size has grown strongly in recent years. It will grow from $4.86 billion in 2024 to $5.23 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth observed during the historical period can be attributed to factors such as the rising incidence of pleural effusion, increasing awareness of pleural diseases, a growing focus on early diagnosis, the expanding number of healthcare facilities, and a rise in pleural disease clinical trials.

The pleural diseases market size is expected to see strong growth in the next few years. It will grow to $6.94 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period is expected to be driven by the increasing prevalence of pleural diseases, the rise in the aging population, a growing number of occupational hazards, an increase in clinical trials, and the expansion of diagnostic centers. Key trends for the forecast period include advancements in diagnostics and diagnostic tools, the adoption of minimally invasive procedures, improved drug development, and the growing adoption of telemedicine.

The rising prevalence of infectious diseases is expected to drive the growth of the pleural diseases market in the coming years. Infectious diseases, caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, are becoming more widespread due to environmental changes, shifts in human behavior, and advancements in global travel. Conditions such as bacterial pneumonia, tuberculosis, or viral infections can lead to pleural disease by causing inflammation, infection, or fluid buildup in the pleural cavity. For example, in January 2023, the National Library of Medicine reported that infectious diseases are responsible for over 52 million deaths annually, putting half of the global population at risk. Furthermore, approximately 14 million children under the age of five die each year, with 70% of these deaths attributed to diseases that could be prevented through vaccination. As the prevalence of infectious diseases increases, it is driving the demand for treatments related to pleural diseases.

Companies in the pleural diseases market are focusing on developing ready-to-use injectable treatments. These pre-formulated and pre-diluted medications require no mixing or reconstitution before administration, ensuring convenience, accuracy, and reduced preparation time. For instance, in April 2024, Amneal Pharmaceuticals, a US-based pharmaceutical company, launched PEMRYDI RTU, the first ready-to-use version of pemetrexed for injection. This innovation provides a convenient treatment for pleural diseases, such as malignant pleural mesothelioma, by eliminating the need for reconstitution, reducing preparation time, minimizing dosing errors, and improving access to effective therapy.

In October 2023, Aileron Therapeutics, a US-based biopharmaceutical company, acquired Lung Therapeutics for an undisclosed amount. This acquisition enhances Aileron’s pipeline with LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusions (LPEs), further strengthening its focus on orphan pulmonary and fibrosis diseases. Lung Therapeutics, also based in the US, is known for developing innovative peptide drugs targeting fibrosis and rare pulmonary conditions.

Major players in the pleural diseases market are Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb Company, GSK plc, Astrazeneca plc, Koninklijke Philips N.V., Becton Dickinson and Company, Boehringer Ingelheim International GmbH, Sanofi SA, Penn Medicine, Henry Ford Health, Dragerwerk AG, Emory Healthcare, Boston Medical Center, Cook Medical, WakeMed, Weill Cornell Medicine, Fox Chase Cancer Center, B. Braun SE, Bicakcilar, Redax S.p.a, Rocket Medical.

North America was the largest region in the pleural diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pleural diseases report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pleural diseases market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pleural diseases refer to a group of conditions that affect the pleura, the double-layered membrane surrounding the lungs. These diseases can involve inflammation, infection, or other pathological changes to the pleura. Symptoms of pleural diseases include chest pain, shortness of breath, coughing, and difficulty breathing, and they are often diagnosed using imaging tests such as chest X-rays or CT scans.

The primary types of pleural diseases include pleurisy, pleural effusion, pneumothorax, mesothelioma, and others. Pleurisy, which involves inflammation of the pleura, causes sharp chest pain and is often linked to infections or autoimmune disorders. Treatment options for pleurisy and other pleural diseases include medications, thoracentesis, pleurodesis, minimally invasive procedures, and surgical interventions. Diagnostic methods include imaging techniques, molecular diagnostics, thoracoscopy, and pleuroscopy. These services are commonly provided in hospitals, clinics, diagnostic centers, and research or academic institutions.

The pleural diseases market research report is one of a series of new reports that provides pleural diseases market statistics, including the pleural diseases industry's global market size, regional shares, competitors with a pleural diseases market share, detailed pleural diseases market segments, market trends and opportunities, and any further data you may need to thrive in the pleural diseases industry. This pleural diseases market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pleural diseases market consist of revenues earned by entities by providing services such as diagnostic, pleurodesis, respiratory therapy, rehabilitation, and biopsy procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The pleural diseases market also includes sales of antibiotics, chemotherapeutic agents, thoracentesis kits, chest tubes and drainage systems, and pleural biopsy needles. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.